Seminars in Hematology
Volume 44, Issue 4 , Pages 246-251 , October 2007

Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia

  • Peter Dreger

      Affiliations

    • Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
    • Corresponding Author InformationAdress correspondence to Peter Dreger, MD, Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
    • ,
  • Ronald Brand

      Affiliations

    • Department of Medical Statistics, University Medical Centre, Leiden, The Netherlands.
    • ,
  • Mauricette Michallet

      Affiliations

    • Department of Hematology, Hôpital Edouard Herriot, Lyon, France.

References 

  1. Gribben JG, Neuberg D, Soiffer RJ, Fisher DC, Schlossman R, Alyea EP, et al. Autologous versus allogeneic bone marrow transplantation for patients with poor prognosis CLL. Blood. 1998;92:322a;(abstr, suppl 1)
  2. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood. 2005;106:4389–4396
  3. Esteve J, Montserrat E, Dreger P, Meloni G, Pavletic S, Catovsky D, et al. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): Outcome and prognostic factors after autologous and allogeneic transplants. Blood. 2001;98:482a;(abstr, suppl 1)
  4. Jantunen E, Itala M, Siitonen T, Juvonen E, Koivunen E, Koistinen P, et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: The Finnish experience. Bone Marrow Transplant. 2006;37:1093–1098
  5. Michallet M, van Biezen A, Bandini G, Carreras E, Cornelissen J, Dreger P, et al. Analysis of prognostic factors on the outcome of autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood. 2001;98:859a;(abstr)
  6. Dreger P, Stilgenbauer S, Busch R, Greinix H, Hensel M, Hertenstein B, et al. Good efficacy but relevant toxicity of early sequential high-dose therapy in genetically poor-risk CLL: Results from the GCLLSG CLL3 protocol. Onkologie. 2005;28(suppl 3):29
  7. Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD, et al. Autografting for younger patients with chronic lymphocytic leukaemia is safe and achieves a high percentage of molecular responses (Results of the MRC pilot study). Blood. 2005;105:397–404
  8. Milligan DW, Kochethu G, Dearden C, Matutes E, MacConkey C, Catovsky D. High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol. 2006;133:173–175
  9. Dreger P, Ritgen M, Böttcher S, Schmitz N, Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: Is achievement of molecular remission worthwile?. Leukemia. 2005;19:1135–1138
  10. Moreno C, Villamor N, Esteve J, Colomer D, Bosch F, Campo E, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;107:4563–4569
  11. Zenz T, Ritgen M, Dreger P, Krober A, Barth TF, Schlenk R, et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;108:2127–2130
  12. Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006;24:2337–2342
  13. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia. 2007;21:12–17
  14. Dreger P, Stilgenbauer S, Benner A, Ritgen M, Kroeber A, Kneba M, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: A risk-matched analysis based on the VH gene mutational status. Blood. 2004;103:2850–2858
  15. Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H, et al. Unmutated immunoglobulin variable heavy chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2003;101:2049–2053
  16. Michallet M, Chevret S, Brand R, van Biezen A, Levy V, Dreger P, et al. Autologous and allogeneic hematopoietic stem cell tranplantations versus conventional chemotherapy in chronic lymphocytic leukemia (CLL): An EBMT and French CLL Cooperative Group study. Blood. 2003;100:39a;(abstr)
  17. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319–2325
  18. Johnson S, Smith AG, Löffler H, Ösby E, Juliusson G, Emmerich B, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin,and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet. 1996;347:1432–1438
  19. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757
  20. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–891
  21. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997. J Clin Oncol. 2007;25:793–798
  22. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz J, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53
  23. Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–4088
  24. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18:1093–1101
  25. Niscola P, Del Principe MI, Maurillo L, Venditti A, Buccisano F, Piccioni D, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia. 2005;19:1840–1841
  26. Dreger P, van Biezen A, Brukx K, Boogaerts M, Michallet M, Milligan D, et al. Treatment-related MDS/AML after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): An EBMT survey. Blood. 2006;106:326a–327a
  27. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: Results of an intergroup study, Cancer and Leukemia Group B 9011. J Clin Oncol. 2002;20:3878–3884
  28. Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica. 2006;91:1546–1550
  29. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant. 2006;37:439–449
  30. Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24:1575–1581
  31. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746–1751
  32. O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1114–1120
  33. Kay NE, Rai KR, O’Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol. 2006;4:1–12
  34. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110–1120
  35. Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: A British Society of Blood and Marrow Transplantation study. Blood. 2006;107:1724–1730

PII: S0037-1963(07)00118-7

doi: 10.1053/j.seminhematol.2007.08.008

Seminars in Hematology
Volume 44, Issue 4 , Pages 246-251 , October 2007

Article Tools

* Image Usage & Resolution